Been in & out of the F/P's a few times over the last six months & currently have exposure for a s/t momentum trade to see where this rally leads.
Am personally very bullish on the potential of SLA relative to market cap vs markets & patent & will probably look at a long position via the SLACB once they resume trading & the dust settles. I did the conversions with SLACA today, & was mighty tempted but alas ... had to go the liquidity!
Am I correct in assuming that if all contributions are made, the company will then have an additional cash injection of >A$770K visible on the next quarterly? Nevertheless, a very interesting type of security! Thanks for your posts & good luck!
Warm regards! : )
********
Solagran Limited Solagran Limited ACN 002 592 396 Level 11 492 St Kilda Road Melbourne 3004 Victoria Australia Tel 61 3 9820 2699 Fax 61 3 9820 3155 11 November, 2004 Company Announcement Contributing Shares (SLACA) Solagran Limited confirms details in regard to the $0.02 per share call on Contributing Shares due on 30 November, 2004. Any Contributing Shareholder who has not received a Call Payment Notice should contact Computershare Investor Services Pty Limited on 1300 557 010. SLACA Contributing Shares (paid to $0.01) will cease trading on ASX on 16 November, 2004. The Contributing Shares (as paid to $0.03) will commence trading on a deferred settlement basis under the new ASX Code of SLACB on 17 November, 2004. The Share Registry will close off all transfers of SLACA Contributing Shares on 19 November, 2004. The Record Date for the call is 23 November, 2004. All Registered Holders of SLACA Contributing Shares on 23 November, 2004 should be aware that if the call of $0.02 per Contributing Share is not paid by 30 November, 2004 then all Contributing Shares with unpaid calls are forfeited for no value. Peter Stedwell Director On behalf of the Board of Directors Solagran Limited Solagran Limited is an Australian company founded in 1995 with the objective of commercialising the results of a research and development program that commenced in Russia in the 1930s, and which has continued, uninterrupted, until the present day. The focus of the research program has been the extraction and utilisation of the “live elements” of tree foliage. Solagran has collectively trademarked these substances using the term Bioeffectives®. Solagran’s technology permits it to obtain many different Bioeffectives from tree and plant sources. One of the highest value Bioeffectives is a class of organic substances known as polyprenols. Polyprenols are naturally occurring precursors of dolichol, which is found in all of the vital organs of the human body, and which plays an essential role in cell metabolism and in supporting the immune system. Solagran has committed significant resources to the development and testing of Bioeffective R – a Bioeffective comprising polyprenols. Experimental results suggest Bioeffective R has a very positive impact on damaged liver cells.
SLA Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
